Home > Products > CD64 & EGFR
> Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Fv-IgG)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Fv-IgG) (CAT#: BSDG-125)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD64 IgG with similar domains from an anti-EGFR antibody via short peptide linkers, or vice versa. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Fv-IgG) (BSDG-125). Click the button below to contact us or submit your feedback about this product.